Literature DB >> 18675690

Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study.

Michael L Jackson1, Jennifer C Nelson, Noel S Weiss, Kathleen M Neuzil, William Barlow, Lisa A Jackson.   

Abstract

BACKGROUND: Pneumonia is a common complication of influenza infection in elderly individuals and could therefore potentially be prevented by influenza vaccination. In studies with data from administrative sources, vaccinated elderly people had a reduced risk of admission for pneumonia compared with unvaccinated seniors; however, these findings could have been biased by underlying differences in health between the groups. Furthermore, since most individuals with pneumonia are not treated in hospital, such studies should include both outpatient and inpatient events. We therefore assessed whether influenza vaccination is associated with a reduced risk of community-acquired pneumonia in immunocompetent elderly people after controlling for health status indicators.
METHODS: We did a population-based, nested case-control study in immunocompetent elderly people aged 65-94 years (cases and controls) enrolled in Group Health (a health maintenance organisation) during the 2000, 2001, and 2002 preinfluenza periods and influenza seasons. Cases were individuals with an episode of outpatient or inpatient community-acquired pneumonia (validated by review of medical records or chest radiograph reports). We randomly selected two age-matched and sex-matched controls for each case. The exposure of interest was influenza vaccination. We reviewed medical records to define potential confounders, including smoking history, presence and severity of lung and heart disease, and frailty indicators.
FINDINGS: 1173 cases and 2346 controls were included in the study. After we adjusted for the presence and severity of comorbidities, as defined by chart review, influenza vaccination was not associated with a reduced risk of community-acquired pneumonia (odds ratio 0.92, 95% CI 0.77-1.10) during the influenza season.
INTERPRETATION: The effect of influenza vaccination on the risk of pneumonia in elderly people during influenza seasons might be less than previously estimated. FUNDING: Group Health Center for Health Studies internal funds and Group Health Community Foundation fellowship grant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18675690     DOI: 10.1016/S0140-6736(08)61160-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  66 in total

1.  Statins and influenza: can we move forward?

Authors:  Edward E Walsh
Journal:  J Infect Dis       Date:  2011-12-13       Impact factor: 5.226

2.  Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.

Authors:  Adrian J Reber; Tatiana Chirkova; Jin Hyang Kim; Weiping Cao; Renata Biber; David K Shay; Suryaprakash Sambhara
Journal:  Aging Dis       Date:  2011-09-30       Impact factor: 6.745

3.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

4.  Estimating the Effect of Influenza Vaccination on Nursing Home Residents' Morbidity and Mortality.

Authors:  Aurora Pop-Vicas; Momotazur Rahman; Pedro L Gozalo; Stefan Gravenstein; Vincent Mor
Journal:  J Am Geriatr Soc       Date:  2015-08-17       Impact factor: 5.562

Review 5.  The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines.

Authors:  Janet E McElhaney; Xin Zhou; H Keipp Talbot; Ernst Soethout; R Chris Bleackley; David J Granville; Graham Pawelec
Journal:  Vaccine       Date:  2012-01-27       Impact factor: 3.641

6.  Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.

Authors:  Sharon K Greene; Martin Kulldorff; Edwin M Lewis; Rong Li; Ruihua Yin; Eric S Weintraub; Bruce H Fireman; Tracy A Lieu; James D Nordin; Jason M Glanz; Roger Baxter; Steven J Jacobsen; Karen R Broder; Grace M Lee
Journal:  Am J Epidemiol       Date:  2009-12-04       Impact factor: 4.897

7.  Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.

Authors:  Dan Yamin; Ran D Balicer; Alison P Galvani
Journal:  Vaccine       Date:  2014-06-12       Impact factor: 3.641

8.  Factors that may impact on immunosenescence: an appraisal.

Authors:  Joseph Ongrádi; Valéria Kövesdi
Journal:  Immun Ageing       Date:  2010-06-14       Impact factor: 6.400

9.  Statin use and risk of community acquired pneumonia in older people: population based case-control study.

Authors:  Sascha Dublin; Michael L Jackson; Jennifer C Nelson; Noel S Weiss; Eric B Larson; Lisa A Jackson
Journal:  BMJ       Date:  2009-06-16

10.  Influenza vaccination and mortality: differentiating vaccine effects from bias.

Authors:  Bruce Fireman; Janelle Lee; Ned Lewis; Oliver Bembom; Mark van der Laan; Roger Baxter
Journal:  Am J Epidemiol       Date:  2009-07-22       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.